Leptin is Implicated in Aromatase Inhibitor Resistance in Breast Cancer Cells

ABSTRACT: Obesity represents a risk factor for breast cancer development and therapy resistance, but the molecular players underling these links are unclear. Here, we identify a role for the obesity-cytokine leptin in sustaining aromatase inhibitor (AI) resistant growth and progression in breast cancer. Using as a cellular model MCF-7 breast cancer cells surviving long-term to the AI treatment Anastrozole (AnaR) and Ana-sensitive counterparts, we found that AnaR cells expressed higher levels of leptin and its receptors (ObR) along with a constitutive activation of downstream effectors. Accordingly, leptin signaling inhibition reduced only AnaR cell growth and motility, highlighting the existence of an autocrine loop in mechanisms governing drug-resistant phenotype. In agreement with ObR overexpressi

INSTRUMENT(S): Illumina HiSeq 2500

ORGANISM(S): Mus musculus

SUBMITTER: Antonio Rinaldi 

PROVIDER: E-MTAB-8843 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress